drugset / Trial / NCT00073762

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

NCT00073762 ↗

Phase 3 Completed 375 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton Psychiatric Rating Scale for Depression, 17-item \[HAM-D17\] less than or equal to 7) versus those subjects receiving placebo.

Timeline

Start
—
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject DVS-233 SR Unknown 200 mg —
Subject DVS-233 SR Unknown 400 mg —